Alpha Cognition Inc ACOG

$9.10 +0.40 (4.60%)

Valuation

Market cap
189,469,000
Revenue TTM
$10,220,000
Net income TTM
$-20,670,000
PE ratio
0.00
Forward PE
—
Profit margin
-202.25%
Debt to equity
0.00

Trading

Volume
194,400
Avg volume
129,082
Day's range
$8.69 – $9.43
Shares out
21,778,000
Stochastic %K
71%
Beta
2.32
Analysts
Strong Sell
Price target
$18.00

Price

Company profile

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-se...

Show more

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

Industry
Biotechnology
Sector
Healthcare
Phone
858 344 4375
Website
https://www.alphacognition.com
Address
1452 Hughes Street, Suite 200, Grapevine, United States

Latest news

Stocktwits

FlowerInTheCellar Oct 3, 6:53 AM
$ACOG https://www.businesswire.com/news/home/20261002072219/en/Alpha-Cognition-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4
0 replies
focafoca99 Oct 3, 12:48 AM
$ACOG announced inducement stock options for a new employee under Nasdaq Rule 5635(c)(4).
0 replies
endrow Oct 1, 1:35 PM
$ACOG Spectacular news, the CONVERGE trial shows that Zunveyl beats the direct competitor drugs by a long-shot! https://www.alphacognition.com/investors/news/alpha-cognition-announces-converge-real-world-evidence-on-zunveylbenzgalantamine-use-in-long-term-care
0 replies
JackCampbell Oct 1, 1:03 PM
$ACOG The CONVERGE study demonstrates high real-world tolerability with an 80% target dose achievement rate among long-term care patients. This validates ZUNVEYL’s GI-friendly prodrug mechanism, providing crucial commercial leverage for broader physician adoption and PBM coverage.
0 replies
JackCampbell Oct 1, 12:55 PM
$ACOG great converge study data now available: https://finance.yahoo.com/healthcare/articles/alpha-cognition-announces-converge-real-123000785.html
0 replies
Squicc Oct 1, 1:08 AM
$ACOG
0 replies
endrow Sep 29, 1:45 PM
$ACOG Opaleye bought another $270000 worth of shares https://www.stocktitan.net/sec-filings/ACOG/form-4-alpha-cognition-inc-insider-trading-activity-b9ebcc1d6e67.html
0 replies
endrow Sep 26, 10:34 AM
$ACOG Don't worry guys, I recently sold some shares so ACOG will probably squeeze in a couple of days now :D
0 replies